ArticleJournal of the American Medical Directors Association2025
Hypertension Treatment, Blood Pressure, and Deprescribing Among US Nursing Home Residents With and Without Dementia Before and After the COVID-19 Pandemic.
Article in Journal of the American Medical Directors Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesTo evaluate hypertension (HTN) management and antihypertensive deprescribing among US nursing home (NH) residents with and without dementia, before and after the onset of the COVID-19 pandemic.
designRetrospective cohort study. SETTING AND
participantsNewly admitted NH residents with HTN treated with an antihypertensive medication who were not receiving hospice from >1100 NHs using a common electronic health record vendor (January 2, 2018-July 3, 2022) (N = 141,630).
methodsDuring an 8-week follow-up period beginning on day 14 in the NH after admission (index date), we measured average blood pressure (BP), BP variability, and prevalence of hypo-/hypertension stratified by dementia status and pre- and post-COVID-19 onset (admission before vs on/after March 11, 2020). We measured antihypertensive medication deprescribing (dose/frequency decreases or cessation for ≥7 days) during a 90-day follow-up and estimated hazard ratios by dementia status using Cox hazards regression models adjusted for demographics and comorbidities. Residents were followed until their first deprescribing event or censoring (discharge, death, 90 days, or July 3, 2022).
resultsBP monitoring was similar between those with and without dementia, but increased post-COVID-19 (eg, 1.6 readings per day pre-COVID-19 vs 1.9 readings per day post-COVID-19 in residents with dementia). Residents with severe dementia had a higher prevalence of hypotension compared with residents without dementia (eg, 16.3% vs 8.9% with at least 1 systolic BP <90 mm Hg among those treated with 2 classes). Residents with dementia were less likely to experience deprescribing than those without dementia (fully adjusted hazard ratio, 0.83; 95% CI, 0.79-0.86). CONCLUSIONS AND IMPLICATIONS: Findings suggest potential overtreatment of HTN among residents with dementia and increased BP monitoring during the COVID-19 pandemic. Results highlight potential opportunities for deprescribing to balance BP control and medication, and monitoring burden in NH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.